ARTICLE | Clinical News
Xtandi reduces radiographic PFS by 61% in metastatic hormone-sensitive prostate cancer
February 15, 2019 7:49 PM UTC
Astellas Pharma Inc. (Tokyo:4503) and Pfizer Inc. (NYSE:PFE) reported that Xtandi enzalutamide plus androgen deprivation therapy (ADT) reduced the risk of radiographic progression or death, the primary endpoint, by 61% vs. ADT alone in the Phase III ARCHES trial to treat metastatic hormone-sensitive prostate cancer (p<0.0001).
Median time to a radiographic progression-free survival (PFS) event in the Xtandi plus ADT arm was not reached; it was 19.4 months for the ADT alone arm...
BCIQ Target Profiles